IN
INTS.US Intensity Therapeutics, Inc. Common stock
- Market cap
- USD 10.2M
- P/E
- -
- P/B
- 1.33x
- ROE
- -156.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is INTS.US undervalued?
Graham numberThe Graham number of Intensity Therapeutics, Inc. Common stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Intensity Therapeutics, Inc. Common stock fundamental analysis
No fundamental analysis for Intensity Therapeutics, Inc. Common stock yet.
Intensity Therapeutics, Inc. Common stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Intensity Therapeutics, Inc. Common stock
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headqua…
Full company profileIntensity Therapeutics, Inc. Common stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Intensity Therapeutics, Inc. Common stock annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | - | - | -179K | -147K | -25.0K | -26.0K | -28.0K |
| Operating Income | -5.68M | -6.22M | -8.01M | -7.55M | -8.32M | -16.6M | -12.0M | -12.3M |
| EBITDA | -5.68M | -6.22M | -8.01M | -7.32M | -10.1M | -16.3M | -11.6M | -12.2M |
| Net Income | -5.23M | -5.96M | -7.89M | -7.58M | -10.5M | -16.3M | -11.6M | -12.0M |
| EPS | -38 | -44 | -58 | -56 | -31 | -29 | -8.56 | -3.68 |
| Balance Sheet | ||||||||
| Total Assets | 9.01M | 10.1M | 5.22M | 1.76M | 17.3M | 4.78M | 14.1M | 10.3M |
| Total Liabilities | 1.31M | 11.7M | 13.9M | 16.9M | 4.13M | 1.87M | 2.23M | 2.64M |
| Shareholders' Equity | 7.70M | -1.56M | -8.68M | -15.1M | 13.2M | 2.92M | 11.9M | 7.65M |
| Cash & Short-term Investments | 8.39M | 9.32M | 4.54M | 1.31M | 14.8M | 2.59M | 11.9M | 8.49M |
| Total Debt | 260K | 497K | 2.34M | 4.49M | 158K | 138K | 110K | 87.0K |
| Cash Flow | ||||||||
| Operating Cash Flow | -4.42M | -5.37M | -6.83M | -5.48M | -7.21M | -15.2M | -9.23M | -8.89M |
| Capital Expenditure | 0.00 | 0.00 | 3.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -4.42M | -5.37M | -6.83M | -5.48M | -7.21M | -15.2M | -9.23M | -8.89M |
| Ratios | ||||||||
| ROE | -67.9% | - | - | - | -80.1% | -557.5% | -97.7% | -156.6% |
| ROA | -58.1% | -58.7% | -151.3% | -431.5% | -60.9% | -340.1% | -82.3% | -116.5% |
| Debt to Equity | 0.03x | - | - | - | 0.01x | 0.05x | 0.01x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
Intensity Therapeutics, Inc. Common stock dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | USD 1.32M | 3.84 | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:25 on Feb 19, 2026.
Who owns Intensity Therapeutics, Inc. Common stock
- Insiders 3.87%
- Institutions 27.23%
- Public & others 68.89%
- Shares outstanding 3.30M
- Free float 3.07M
Top funds holding INTS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 11.7K | 0.35% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 3.25K | 0.10% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 3.09K | 0.09% | 0.00% | Sep 2026 |
Top institutions holding INTS.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Kingsbury Capital Investment Advisors LLC | 707K | 21.64% | +42.30% | Sep 2026 |
| KMT WEALTH MANAGEMENT, LLC | 496K | 15.21% | 0.00% | Jun 2026 |
| Sentinus, LLC | 26.7K | 0.82% | +14.72% | Jun 2026 |
| Vanguard Capital Management, LLC | 26.6K | 0.81% | +57.76% | Jun 2026 |
| NANO CAP NEW MILLENNIUM GROWTH FUND L P | 25.0K | 0.77% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 22.8K | 0.70% | -12.42% | Jun 2026 |
| Mesirow Fin Investmt Mgmt Intl Equity | 14.1K | 0.43% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 9.12K | 0.28% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 1.98K | 0.06% | +2,861.19% | Jun 2026 |
| Goss Wealth Management LLC | 1.15K | 0.04% | 0.00% | Jun 2026 |
| Advisor Group Holdings, Inc. | 200.00 | 0.01% | 0.00% | Jun 2026 |
| Mercer Global Advisors Inc. | 48.00 | 0.00% | 0.00% | Jun 2026 |
| Barclays PLC | 42.00 | 0.00% | 0.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 20.00 | 0.00% | 0.00% | Jun 2026 |
| Caitong International Asset Management Co., Limited. | 6.00 | 0.00% | 0.00% | Jun 2026 |
| UBS Group AG | 1.00 | 0.00% | -99.48% | Jun 2026 |
| Wells Fargo & Co | 0.00 | 0.00% | -100.00% | Jun 2026 |
Intensity Therapeutics, Inc. Common stock company profile
- Company name
- Intensity Therapeutics, Inc. Common stock
- Ticker
- INTS.US
- Exchange
- USA Stocks
- Listed since
- Jun 30, 2023
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 5
- Fiscal year end
- December
- Address
- 1 Enterprise Drive, Shelton, CT, United States, 06484-4779
- Phone
- 203 221 7381
- Website
- intensitytherapeutics.com
About Intensity Therapeutics, Inc. Common stock
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
Intensity Therapeutics, Inc. Common stock management
4- Mr. Lewis H. Bender M.A., M.B.A., M.S.Founder, President, CEO & Chairman of the Board · born 1959
- Mr. Joseph Talamo CPA, M.B.A.Chief Financial Officer · born 1969
- Mr. John Wesolowski CPA, M.B.A.Principal Accounting Officer & Controller · born 1960
- Mr. James M. AhlersExecutive Vice President of Corporate Finance · born 1964